$IRON

Khara Rahul sold $400K of IRON

Khara Rahul (Chief Legal Officer) sold 5,000 shares of Disc Medicine, Inc. (IRON) at $80.00 ($0.40M total) on 2026-08-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Khara Rahul
Published Aug 7, 2026, 9:32 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 9:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IRON
Neutral
medium confidence
Mentioned
$IRON
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRONNeutralLow
01

Why it matters

The only new information is the reported sale size, price, and that it was executed under a pre-arranged 10b5-1 plan. No new guidance, trial result, or corporate action is disclosed.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 structure and lack of fundamental updates limit trading impact.

03

What to watch

The article does not state whether the insider’s remaining holdings or other insider activity changed, nor does it provide any company-specific news that would connect the sale to fundamentals.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-07 after-hours; transaction dated 2026-08-06

Background

The article is a SEC Form 4 insider transaction disclosure for Disc Medicine, Inc. (IRON).

Company-level read

Ticker impact

$IRONNeutralMedium confidence
Context

Disc Medicine (IRON) disclosed an insider Form 4 sale by Chief Legal Officer Khara Rahul of 5,000 shares at $80 on 2026-08-06 under a 10b5-1 plan.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional signal beyond typical insider selling.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, which generally reduces interpretive weight versus discretionary sales. The article provides no new operational, financial, or regulatory catalyst for IRON.

Market effects

Minimal. Insider 10b5-1 selling in a single biotech name typically does not reset sector expectations.

Minimal.

Minimal.

Counterpoint

A 10b5-1 sale can be purely mechanical and may not reflect bearish views; traders may overreact to the headline framing of “sold.”

Key entities

  • Disc Medicine, Inc.

    Subject of the Form 4 insider transaction disclosure (IRON).

  • Khara Rahul

    Chief Legal Officer who sold 5,000 shares under a 10b5-1 plan.

Related articles

$IRONMed

Disc Medicine, Inc. (IRON): Results of Operations and Financial Condition

Disc Medicine, Inc. (IRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 iron-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update • Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis f

$NEEMed

SMALL-CAP MOVERS: Britain's bargain basement and the overseas buyers who can't believe their luck

The article reports AIM takeover activity: Gooch & Housego PLC is being acquired in a £346m deal, and Ramsdens Holdings PLC is set to be bought for £230m. It also notes NextEnergy Solar rose 10% after putting itself up for sale, and highlights large AIM share moves for Ironveld, Itaconix, Jersey Oil and Gas, Safestay, Galileo Resources, and Iofina. Iofina reported 393.3 tonnes H1 2026 and raised guidance to 460-485 tonnes.

$IRONMed

Ironveld shares jump 32% at 0.025p as processing plant hits sustained production

Ironveld PLC (AIM:IRON) shares rose 32% to 0.025p after the company said its dense media separation plant reached sustained production. It now runs 16 hours daily on double shift, processing 2.5-3.5 tonnes per hour and producing 1.4 tonnes/hour in-spec magnetite plus about 1 tonne/hour maghemite. Three clients secured, with a 5,000 tonnes/month buyer sampling; expansion options and Mintek study ongoing.

$IRONMed

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

Disc Medicine (NASDAQ:IRON) reported updated clinical data at the 2026 EHA meeting in Stockholm. In RALLY-MF, DISC-0974 showed durable overall anemia responses in myelofibrosis across subgroups, including 55% major hemoglobin response in non-transfusion dependent patients and transfusion independence in 64% (TD Low) and 50% (TD High). In HELIOS, bitopertin sustained PPIX reductions and improved light tolerance with favorable longer-term safety. A corporate call is set for June 15.

$IRONLow

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Rosen Law Firm said it is investigating potential securities claims for Disc Medicine, Inc. (NASDAQ: IRON) shareholders, alleging materially misleading business information. The firm cited an FDA Complete Response Letter on Feb. 13, 2026 for Disc Medicine’s bitopertin NDA, citing uncertainties needing more evidence; IRON shares fell 22% that day.

$IRONLow

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Rosen Law Firm said it is investigating potential securities claims for Disc Medicine, Inc. (NASDAQ: IRON) investors over allegations of materially misleading business information. The firm cited an FDA Complete Response Letter on Feb. 13, 2026 for Disc Medicine’s bitopertin NDA, citing uncertainties needing more evidence; IRON shares fell 22% that day.